| Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 8400346 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose bowel movements within 4 days of therapy, while in the loperamide group this goal was obtained in only 30% of cases (p < 0.001). If after 4 days no benefit was seen, patients were considered to have failed antidiarrheal therapy. Failure was recorded in only one case (5%) treated with s.c. octreotide and in five patients (25%) who received loperamide. The mean duration of antidiarrheal therapy necessary to achieve remission was 3.4 days in the octreotide group and 6.1 days in the loperamide group (p < 0.001). Treatment with octreotide was very well tolerated with mild abdominal pain in 15% of cases and pain in the injection site in 15% of patients. Subcutaneous octreotide is highly effective in the management of chemotherapy-related diarrhea in cancer patients. |
| | |
Authors:
|
V Gebbia; I Carreca; A Testa; R Valenza; G Curto; G Cannata; N Borsellino; M A Latteri; C Cipolla; M Florena |
Related Documents
:
|
17321236 - Frequency and severity of post-ercp pancreatitis correlated with extent of pancreatic d... 12500836 - Ercp's role in the management of acute biliary-pancreatic pathology in the laparoscopic... 23475126 - Short-term outcome and patient satisfaction after sialendoscopy. 11717716 - Invasive enteritis by strongyloides stercoralis presenting as acute abdominal distress ... 2204696 - Quality of life after heart transplantation in patients assigned to double- or triple-d... 10997066 - Does indermil glue improve success rates in myringoplasty? interim analysis of a prospe... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Anti-cancer drugs Volume: 4 ISSN: 0959-4973 ISO Abbreviation: Anticancer Drugs Publication Date: 1993 Aug |
Date Detail:
|
Created Date: 1993-11-15 Completed Date: 1993-11-15 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9100823 Medline TA: Anticancer Drugs Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 443-5 Citation Subset: IM |
Affiliation:
|
University of Palermo, Chair and Service of Chemotherapy, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Antineoplastic Combined Chemotherapy Protocols / adverse effects* Diarrhea / chemically induced*, drug therapy* Female Humans Injections, Subcutaneous Loperamide / adverse effects, therapeutic use* Male Middle Aged Neoplasms / drug therapy Octreotide / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
53179-11-6/Loperamide; 83150-76-9/Octreotide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bioavailability of a new oral formulation of medroxyprogesterone acetate compared with the standard ...
Next Document: XB596, a promising bis-naphthalimide anti-cancer agent.